Dipeptidyl peptidase-4: a key player in chronic liver disease.
about
Role of biomarkers in the prediction and diagnosis of hepatocellular carcinomaDPP4 in DiabetesIncretin based therapies: a novel treatment approach for non-alcoholic fatty liver diseaseTissue distribution of teneligliptin in rats and comparisons with data reported for other dipeptidyl peptidase-4 inhibitors.Identification of novel dipeptidyl peptidase 9 substrates by two-dimensional differential in-gel electrophoresis.Retrospective study of the associations between hepatitis C virus infection and metabolic factors.Linagliptin alleviates fatty liver disease in diabetic db/db micePharmacokinetic and toxicological considerations for the treatment of diabetes in patients with liver disease.Pharmacokinetics in patients with chronic liver disease and hepatic safety of incretin-based therapies for the management of type 2 diabetes mellitus.A review of gliptins for 2014.Safety of dipeptidyl peptidase-4 inhibitors for treating type 2 diabetes.An updated review on cancer risk associated with incretin mimetics and enhancers.Current Concepts in Diabetes Mellitus and Chronic Liver Disease: Clinical Outcomes, Hepatitis C Virus Association, and Therapy.Influence of nutritional intervention on children with type 1 diabetes mellitus and DPP-4 in serum.GLP-1 signalling compensates for impaired insulin signalling in regulating beta cell proliferation in βIRKO mice.Hepatogenous diabetes: Is it time to separate it from type 2 diabetes?Circulating dipeptidyl peptidase-4 activity correlates with measures of hepatocyte apoptosis and fibrosis in non-alcoholic fatty liver disease in type 2 diabetes mellitus and obesity: A dual cohort cross-sectional study.Dipeptidylpeptidase-IV activity and expression reveal decreased damage to the intrahepatic biliary tree in fatty livers submitted to subnormothermic machine-perfusion respect to conventional cold storage.Hypoxia Alters the Expression of Dipeptidyl Peptidase 4 and Induces Developmental Remodeling of Human Preadipocytes.Elevated hepatic DPP4 activity promotes insulin resistance and non-alcoholic fatty liver disease.Bullous Pemphigoid Associated with the Dipeptidyl Peptidase-4 Inhibitor Sitagliptin in a Patient with Liver Cirrhosis Complicated with Rapidly Progressive Hepatocellular Carcinoma.A fluorescent switchable AIE probe for selective imaging of dipeptidyl peptidase-4 in vitro and in vivo and its application in screening DPP-4 inhibitors.Vildagliptin: any effect on non-alcoholic fatty liver disease and serum uric acid? Re: Shelbaya S, Rakha S. Effectiveness and safety of vildagliptin and vildagliptin add-on to metformin in real-world settings in Egypt - results from the GUARD study.KLK5 induces shedding of DPP4 from circulatory Th17 cells in type 2 diabetes.Significance of circulatory DPP4 activity in metabolic diseases.Neuroprotective effects of vildagliptin in rat rotenone Parkinson's disease model: role of RAGE-NFκB and Nrf2-antioxidant signaling pathways.Enzyme-Histochemistry Technique for Visualizing the Dipeptidyl-Peptidase IV (DPP-IV) Activity in the Liver Biliary Tree.Synthetic lethal interaction of combined CD26 and Bcl-xL inhibition is a powerful anticancer therapy against hepatocellular carcinoma.The protective effect of vildagliptin in chronic experimental cyclosporine A-induced hepatotoxicity.Effect of sitagliptin on hepatic histological activity and fibrosis of nonalcoholic steatohepatitis patients: a 1-year randomized control trial.Vildagliptin Can Alleviate Endoplasmic Reticulum Stress in the Liver Induced by a High Fat Diet.Sitagliptin reduces insulin resistance and improves rat liver steatosis via the SIRT1/AMPKα pathway
P2860
Q26781469-37509C2B-8B6D-4464-B634-73B7284CD140Q26797335-EBB6A5E8-6450-45DE-B71C-D07BD09E6E63Q26827183-A14FFA92-76C8-4745-820D-22DDDC6ED373Q31036099-6DFE36DF-000C-498F-A22F-EE8268F10837Q35691528-F19D3165-519C-4B70-B89D-248AD3AA8D1FQ37374053-D903C49A-B1FF-4341-BD5B-DD1FCD903EBBQ37411528-CBB9E560-1C5A-4799-91E3-45D281C98C2AQ38199526-3A8E5EB3-9D9C-473C-8F20-36DD4B088304Q38236774-E54B6656-485B-40B8-A4E9-2F0C09B17FEFQ38266290-AD8DEDF9-AF97-4171-BC03-93CDE5FD1FEFQ38335751-2A866ACA-3377-4188-9805-E36C7AAF176CQ38388920-16EFF225-8360-4AA1-9A40-9442E4ABECCFQ38606170-6C4833B0-3E0C-4E3F-919F-7C7A45630587Q38638016-81A69EE9-8433-4356-89E2-A957160A4A2CQ38773675-0CA7CE04-1B48-4EFA-A93E-D574849857C0Q39036315-49998C19-465D-4972-AF15-DB74739A14A1Q41686499-CB88021F-0902-40EF-92F8-3ED881700F4AQ41851708-87F73EDF-4332-4B70-B61E-68F11A739F2DQ41877149-D2C71FB1-C1A4-41AF-ABC5-08F7E2DA80F2Q42377919-58AB569D-79DC-435F-9DD8-9C4765F10EE6Q42378749-126971E8-3920-4343-A16F-2AC13AE61E7EQ42815001-C50C117A-6AB1-4ECC-8BD4-929071100ED0Q46357255-FB235DFB-F94D-48FC-AF06-15326D27BE33Q47150494-391689D6-6074-403B-8DEC-9036FB9E2FE1Q48249200-44324AC6-60CC-4AFE-A8E0-7982816DF3E0Q48290344-7CC9ADE3-2D45-4CED-B32D-E2F7D2260178Q51155176-3CF956BD-FF61-434F-B89D-C634FE62B65EQ52305766-435CD18D-A95F-4361-BD35-555AA47B3190Q53780989-4CF5D152-3B5A-40B7-8A5A-B505FBD5D58BQ55175731-5473F662-549D-498E-BAC9-259DC0713FFEQ55253186-5160169E-22BE-49F1-A915-6554E423971AQ58804681-DA286F1B-F58F-496A-B3F7-0CC4A7981DD5
P2860
Dipeptidyl peptidase-4: a key player in chronic liver disease.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
2013年论文
@zh
2013年论文
@zh-cn
name
Dipeptidyl peptidase-4: a key player in chronic liver disease.
@en
type
label
Dipeptidyl peptidase-4: a key player in chronic liver disease.
@en
prefLabel
Dipeptidyl peptidase-4: a key player in chronic liver disease.
@en
P2093
P2860
P356
P1476
Dipeptidyl peptidase-4: a key player in chronic liver disease.
@en
P2093
Eitaro Taniguchi
Michio Sata
Minoru Itou
Takumi Kawaguchi
P2860
P304
P356
10.3748/WJG.V19.I15.2298
P407
P577
2013-04-01T00:00:00Z